RESULTS	Year 5 radiographs demonstrated mean changes in modified total Sharp score for the original adalimumab 40 mg eow and 20 mg weekly groups of 0.8 and 2.6 , respectively , versus 3.9 for placebo ; 58 % from the adalimumab 40 mg eow group had no radiographic progression versus 40 % of those who initially received placebo .\